Research Publications

APAC'S Research


Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN (dendritic cell-based vaccine): a case report

Oropharyngeal Carcinoma is one of the most common head and neck cancers. Over 90% of the oropharyngeal cancers are squamous cell carcinoma in origin with a yet undetermined percentage being adenocarcinoma . Adenocarcinoma is a common malignancy emerging from minor salivary glands, and in other organs such as lung, prostate, pancreas, colon, esophagus, and the oropharyngeal area. The most common region for oropharyngeal adenocarcinoma is the superficial lobe of the parotid gland, followed by the...

: by Chaitanya Kumar , Sakshi Kohli, Srikanth Chiliveru, Minish Jain & Bandana Sharan

Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care

Metastases are the primary cause of death in patients with solid cancers (1,2). Cancer accounts for approximately 7% of deaths in India and 23% in the United States, with a prevalence of 2.5 million and approximately 0.8 million new cases each year in India (3). Chemotherapy has been in the mainstay of cancertreatmentandhasbeenfoundtobeeffectivein various types of cancer, but metastatic malignancies often develop resistance to standard chemotherapies, which are also responsible for considerable ...

: by POONAMALLE PARTHASARATHY BAPSY, BANDANA SHARAN, CHAITANYA KUMAR, RAJEEV PATRICK DAS, BHARATH RANGARAJAN, MINISH JAIN, VENKATA SATHYA SURESH ATTILI, SUNDARAM SUBRAMANIAN, SHYAM AGGARWAL, MALA SRIVASTAVA & ASHOK VAID

Apceden Immunotherapy Research

Apceden is an autologous (self) monocyte derived Dendritic Cell (DC) based immunotherapy which activates the patients immune system against specific cancer. It is believed to act by stimulating the production of immune cells, produced naturally in the body, that target and attack cancer cells. The Dendritic Cell itself is an immune cell involved in the recognition, processing and presentation of foreign antigens to the T-cells in the effector arm of the immune system. Although Dendritic Cells ar...

: by APAC Biotech Pvt. Ltd

A retrospective analysis comparing APCEDENR dendritic cell immunotherapy with best supportive care in refractory cancer.

A retrospective survival benefit analysis of APCEDEN R , APAC BIOTECH Pvt Ltd 69, Jacranda Marg, DLF PHASE II, Gurugram, Haryana, India, an autologous dendritic cell-based product for management of refractory solid malignancies, was performed in comparison with a control group. Methods: Subjects (retrospective data) whose survival data, geographical region, age, gender, ECOG performance status and stage of disease that could be matched with the treatment group were considered for analysis.Resul...

: by Chaitanya Kumar1, Sakshi Kohli1, Srikanth Chiliveru, Poonamalle Parthasarathy Bapsy, Minish Jain, Venkata Sathya Suresh Attili, Jagan Mohan, Ashok K Vaid & Bandana Sharan.

Immune modulation by dendritic-cell-based cancer vaccines

Harnessing the potential of the immune system to fight cancer relies on the delicate balance between anti-tumour and protumourimmunity. Understanding of the host immune responses to tumours and the evasion strategies employed by the tumour to escape attack by immune cells becomes essential to determine the treatment options specific to killing tumours with minimal toxicity to host cells. Immunotherapy drugs have been characterized into immune checkpoint inhibitors, monoclonal antibodiestargeting...

: by CHAITANYA KUMAR , SAKSHI KOHLI, POONAMALLE PARTHASARATHY BAPSY, ASHOK KUMAR VAID, MINISH JAIN, VENKATA SATHYA SURESH ATTILI and BANDANA SHARAN
©2017 - 2018 Apac Biotech Pvt Ltd. All Rights Reserved.